These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 8034392)

  • 1. Who needs faster drug approval times in Canada: the public or the industry?
    Lexchin J
    Int J Health Serv; 1994; 24(2):253-64. PubMed ID: 8034392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The timeliness of new drug approvals in Canada.
    Rawson NS
    Int J Health Serv; 1995; 25(1):153-65; discussion 167-71. PubMed ID: 7794387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Pharmaceutical Industry and the Canadian Government: Folie à Deux.
    Lexchin J
    Healthc Policy; 2017 Aug; 13(1):10-16. PubMed ID: 28906232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
    Beatty PA; Laking GR
    J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
    [No Abstract]   [Full Text] [Related]  

  • 7. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
    Rawson NS
    CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study.
    Lexchin J
    Ann Pharmacother; 2006 Dec; 40(12):2216-22. PubMed ID: 17132811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
    DerGurahian J
    Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
    [No Abstract]   [Full Text] [Related]  

  • 11. [Medications: dear and expensive?].
    Rojahn J
    Klin Monbl Augenheilkd; 2014 Feb; 231(2):108-13. PubMed ID: 25298981
    [No Abstract]   [Full Text] [Related]  

  • 12. [Medication prices in Germany--how are they determined?].
    Bruhn C
    Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
    [No Abstract]   [Full Text] [Related]  

  • 13. [The AMNOG and its consequences].
    Dingermann T
    Internist (Berl); 2013 Jun; 54(6):769-74. PubMed ID: 23475259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 15. Industry and regulatory performance in 2012: a year in review.
    Dowden HM; Jahn R; Catka T; Jonsson A; Michael E; Miwa Y; Zinkand W
    Clin Pharmacol Ther; 2013 Sep; 94(3):359-66. PubMed ID: 23657160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. After compulsory licensing: coming issues in Canadian pharmaceutical policy and politics.
    Lexchin J
    Health Policy; 1997 Apr; 40(1):69-80. PubMed ID: 10165902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs and indications in 2012. Sluggish progress, timid measures to protect patients.
    Prescrire Int; 2013 Apr; 22(137):105-7. PubMed ID: 23662323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 19. [The German law on reorganization of the pharmaceutical market (AMNOG): distinction between innovations and pseudoinnovations].
    Doht C
    Internist (Berl); 2013 Oct; 54(10):1274. PubMed ID: 24026791
    [No Abstract]   [Full Text] [Related]  

  • 20. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology.
    van der Greef J; McBurney RN
    Nat Rev Drug Discov; 2005 Dec; 4(12):961-7. PubMed ID: 16341061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.